Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...

Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...

The majority of bladder cancers are diagnosed as non-muscle invasive (NMIBC), with 90% over the age of 55. Although the incidence of several malignancies is increasing among younger adults in whom ...

Neeraj Agarwal discusses TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus ...

Cystoscopy and urinary cytology are the gold standard tools for monitoring non-muscle-invasive bladder cancer (NMIBC). A new biomarker-based test (Xpert® Bladder Cancer Monitor) has been developed to ...

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) frequently coexists with erectile dysfunction (ED) and is associated with substantial impairment in quality of life (QoL). Although ...

At the 2026 UCSF-UCLA PSMA Conference, Jonathan Chou reviews non-PARP DNA repair targets as radiosensitizers for radiopharmaceutical therapy, highlighting a CRISPR-Cas9 functional genomics screen ...

Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHHiP radiotherapy fractionation trial in localized prostate cancer. The MMAI ...

Silke Gillessen speaks with Neeraj Agarwal about the Advanced Prostate Cancer Consensus Conference, marking its 10th anniversary edition in Lugano. Dr. Gillessen describes APCCC's focus on daily ...